Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

Ver Toda la documentación

Y0001327

Atorvastatin calcium trihydrate

European Pharmacopoeia (EP) Reference Standard

Sinónimos:

Atorvastatin hemicalcium salt sesquihydrate

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C66H68CaF2N4O10 · 3H2O
Número de CAS:
344423-98-9
Peso molecular:
1209.39
Código UNSPSC:
41116107
NACRES:
NA.24

grado

pharmaceutical primary standard

familia API

atorvastatin

fabricante / nombre comercial

EDQM

aplicaciones

pharmaceutical (small molecule)

Formato

neat

temp. de almacenamiento

2-8°C

InChI

1S/2C33H35FN2O5.Ca.3H2O/c2*1-21(2)31-30(33(41)35-25-11-7-4-8-12-25)29(22-9-5-3-6-10-22)32(23-13-15-24(34)16-14-23)36(31)18-17-26(37)19-27(38)20-28(39)40;;;;/h2*3-16,21,26-27,37-38H,17-20H2,1-2H3,(H,35,41)(H,39,40);;3*1H2/q;;+2;;;/p-2/t2*26-,27-;;;;/m11..../s1

Clave InChI

SHZPNDRIDUBNMH-NIJVSVLQSA-L

¿Está buscando productos similares? Visita Guía de comparación de productos

Descripción general

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicación

Atorvastatin calcium trihydrate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Envase

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Otras notas

Sales restrictions may apply.

Producto relacionado

Referencia del producto
Descripción
Precios

1044516

Atorvastatin Calcium, United States Pharmacopeia (USP) Reference Standard

1044527

Atorvastatin Related Compound A, United States Pharmacopeia (USP) Reference Standard

1044538

Atorvastatin Related Compound B, United States Pharmacopeia (USP) Reference Standard

1044549

Atorvastatin Related Compound C, United States Pharmacopeia (USP) Reference Standard

1044550

Atorvastatin Related Compound D, United States Pharmacopeia (USP) Reference Standard

1044571

Atorvastatin Related Compound E, United States Pharmacopeia (USP) Reference Standard

Y0001329

Atorvastatin impurity B, European Pharmacopoeia (EP) Reference Standard

Y0001332

Atorvastatin impurity E, European Pharmacopoeia (EP) Reference Standard

1044593

Atorvastatin Related Compound I, United States Pharmacopeia (USP) Reference Standard

1044582

Atorvastatin Related Compound H, United States Pharmacopeia (USP) Reference Standard

PHR1873

Atorvastatin Related Compound H, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1869

Atorvastatin Related Compound B, pharmaceutical secondary standard, certified reference material

PHR1872

Atorvastatin Related Compound E, pharmaceutical secondary standard, certified reference material

PHR1874

Atorvastatin Related Compound I, pharmaceutical secondary standard, certified reference material

PHR1870

Atorvastatin Related Compound C, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1871

Atorvastatin Related Compound D, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1868

Atorvastatin Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2421

1,1-Dimethylethyl (4R-cis)-6-Aminoethyl-2,2-dimethyl-1,3-dioxane-4-acetate

Y0002315

Atorvastatin calcium, CRS, European Pharmacopoeia (EP) Reference Standard

Pictogramas

Health hazard
GHS08

Palabra de señalización

Danger

Frases de peligro

H351,H360D

Clasificaciones de peligro

Carc. 2 - Repr. 1B

Código de clase de almacenamiento

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Clase de riesgo para el agua (WGK)

WGK 3

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Los clientes también vieron

Slide 1 of 3

1 of 3

Atorvastatin Related Compound B United States Pharmacopeia (USP) Reference Standard

USP

1044538

Atorvastatin Related Compound B

Atorvastatin Related Compound A United States Pharmacopeia (USP) Reference Standard

USP

1044527

Atorvastatin Related Compound A

Ezetimibe United States Pharmacopeia (USP) Reference Standard

USP

1269028

Ezetimibe

Hongshi Li et al.
Cardiovascular journal of Africa, 30(5), 268-274 (2019-07-31)
Our previous experiments showed that the transient sodium current (INa) was abnormally increased in early ischaemia and atorvastatin could inhibit INa. The aim of this study was to observe the time-dependent effects of simulated ischaemia on INa and characterise the
Fang Hu et al.
AMB Express, 9(1), 37-37 (2019-03-20)
The aim of the present study was to evaluate the protective effects of combined atorvastatin and amygdalin in a rat model of endometriosis. Tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), matrix metalloproteinase-2 (MMP-2) and MMP-9 levels in the peritoneal fluid were
Hui-Hui Li et al.
Acta pharmacologica Sinica, 41(3), 327-335 (2019-07-31)
23,24-Dihydrocucurbitacin B (designated as C95 in this article) is a cucurbitane triterpenoid that has been shown to possess a variety of pharmacological activities, such as anti-inflammatory and anti-HIV-1 activities etc. In this study, we investigated the effects of 23,24-dihydrocucurbitacin B
Masaki Watanabe et al.
Drug metabolism and pharmacokinetics, 30(2), 198-204 (2015-05-21)
Since drug-drug interaction (DDI) can affect organic anion-transporting polypeptide (OATP) and cause clinical events, prediction of such DDI is important in early clinical development. Although statins are useful probes for OATP-mediated DDI, endogenous probes would be more practical for predicting
Alexander Treiber et al.
The Journal of pharmacology and experimental therapeutics, 350(1), 130-143 (2014-04-29)
Treatment of pulmonary arterial hypertension with the endothelin receptor antagonist bosentan has been associated with transient increases in liver transaminases. Mechanistically, bosentan inhibits the bile salt export pump (BSEP) leading to an intrahepatic accumulation of cytotoxic bile salts, which eventually

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico